Entera Bio Ltd. Overview
Pro stress-test →Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies for unmet medical needs, leveraging its proprietary N-Tab platform that stabilizes peptides and promotes absorption into the bloodstream. The company is addressing large markets including osteoporosis, hypoparathyroidism, obesity, and rare malabsorption conditions where oral delivery could transform treatment paradigms currently dominated by injectable therapies.
Strategic Profile
Pro stress-test →Entera achieved FDA alignment for EB613 in July 2025 and is pursuing strategic partnership discussions to optimize development and commercialization across its pipeline. The company appointed former Pfizer executive Geno J. Germano as Chairman in February 2026, signaling institutional strengthening ahead of key clinical milestones.
Competitive Landscape
Pro stress-test →Entera competes in multiple therapeutic areas including oral GLP-1/glucagon peptides for obesity and GLP-2 for short bowel syndrome, currently dominated by injectable alternatives like semaglutide and Gattex. The company's primary competitive advantage is its N-Tab platform enabling oral delivery of large molecules where existing therapies require daily injections.
Industry Context
Entera Bio Ltd. operates in Biopharmaceutical - Specialty Therapeutics (Oral Peptide Delivery).
Key facts
Founded: 2009 · Headquarters: Jerusalem, Israel